Abstract: An object of the present invention is to provide a novel cell for ex vivo gene therapy which produces a FVIII variant. The cell for ex vivo gene therapy of the present invention as a solution thereof produces a variant of human FVIII having the amino acid sequence at positions 20 to 2351 of the amino acid sequence of SEQ ID NO: 1 in which the B domain (the amino acid sequence at positions 760 to 1667) has been modified, thereby, the number of Asn residues subjected to N-linked glycosylation is four to six from the N-terminus and the function of the furin recognition site is lacking.

Abstract: An object of the present invention is to provide a liquid composition for external application and a preparation for external application which are excellent in healing effect on skin ulcers including intractable skin ulcers such as bedsore (decubitus), diabetic skin ulcer and ischemic skin ulcer. The liquid composition for external application of the present invention as means for the resolution is characterized by comprising at least G-CSF (a granulocyte colony stimulating factor) as an active ingredient and 0.001% to 5% of alginic acid. The preparation for external application for treatment of a skin ulcer of the present invention is characterized by comprising the liquid composition for external application of the present invention as a medicinal ingredient.

Abstract: [Problems] To provide a novel external agent for treatment of skin ulcer which has an excellent healing effect on intractable skin ulcer such as bedsore, diabetic skin ulcer and ischemic skin ulcer. [Means for Solving Problems] The agent is characterized in that it comprises a composition containing at least one selected from the group consisting of granulocyte colony stimulating factor (G-CSF), stromal cell-derived factor-1 (SDF-1) and CD41-positive cells, and a hydrophilic high molecular substance.